<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02711059</url>
  </required_header>
  <id_info>
    <org_study_id>KarolinskaUH_pHPT_diabetes</org_study_id>
    <nct_id>NCT02711059</nct_id>
  </id_info>
  <brief_title>Insulin Resistance in Primary Hyperparathyroidism</brief_title>
  <acronym>IRIPH</acronym>
  <official_title>Insulin Resistance in Primary Hyperparathyroidism, a Non-classical Manifestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study is to analyse if insulin resistance in primary hyperparathyroidism
      (pHPT) is normalised after parathyroid adenomectomy and if glucose tolerance test may be
      useful as a diagnostic tool by predicting potential improvement of insulin sensitivity after
      biochemical cure of pHPT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To be conducted at the Karolinska University Hospital, Stockholm. Patients with fb-glucos
      &gt;6.1 and HbA1c without medical treatment will be included after informed consent and
      randomised to parathyroidectomy (PTX) within three months or not. The groups will be examined
      4 ±4 weeks before and 12±2 weeks after PTX, similar for the control group. The number of
      participants will be estimated by power calculations based on a pilot study including 20
      patients.

      The test protocol includes glucose load with control of glucose and insulin, (0, 30, 60 and
      120 min) together with measurement of markers of oxidative stress and inflammation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glucose tolerance test with estimation of insulin resistance</measure>
    <time_frame>6 months</time_frame>
    <description>Homa IR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>self estimation protocol EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>psychological wellbeing</measure>
    <time_frame>6 months</time_frame>
    <description>POMS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anxiety, depression</measure>
    <time_frame>6 months</time_frame>
    <description>HAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognition</measure>
    <time_frame>6 months</time_frame>
    <description>MoCA-Test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hyperparathyroidism</condition>
  <condition>Diabetes</condition>
  <condition>Hypercalcemia</condition>
  <arm_group>
    <arm_group_label>parathyroidectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>change in insulin resistance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>the study participant will be examined parallel with the active comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>parathyroidectomy</intervention_name>
    <description>surgical treatment of hyperparathyroidism</description>
    <arm_group_label>parathyroidectomy</arm_group_label>
    <other_name>parathyroid adenomectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary hyperparathyroidism and fb-glukos&gt;6,1 and/or HbA1c &gt; 39 mmol/mol

        Exclusion Criteria:

          -  Treatment with insulin, sulfonylurea or metformin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inga-Lena Nilsson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Universitetssjukhuset</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ylva Pernow, MD, PhD</last_name>
    <phone>+46739789188</phone>
    <email>ylva.pernow@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inga-Lena Nilsson, MD, PhD</last_name>
      <phone>+46702167535</phone>
      <email>inga-lena.nilsson@ki.se</email>
    </contact>
    <contact_backup>
      <last_name>Rebecka Hallbeck, Res. ass.</last_name>
      <phone>+46725836757</phone>
      <email>rebecka.hallbeck@karolinska.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.viss.nu/Handlaggning/Vardprogram/Endokrina-organ/Prediabetes/</url>
    <description>Regional program</description>
  </link>
  <reference>
    <citation>Norenstedt S, Pernow Y, Brismar K, Sääf M, Ekip A, Granath F, Zedenius J, Nilsson IL. Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study. Eur J Endocrinol. 2013 Oct 21;169(6):795-804. doi: 10.1530/EJE-13-0547. Print 2013 Dec.</citation>
    <PMID>24026893</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2016</study_first_posted>
  <last_update_submitted>October 16, 2016</last_update_submitted>
  <last_update_submitted_qc>October 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Inga-Lena Nilsson</investigator_full_name>
    <investigator_title>MD, PhD, consultant surgeon</investigator_title>
  </responsible_party>
  <keyword>hyperparathyroidism</keyword>
  <keyword>insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
    <mesh_term>Hypercalcemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

